What is Birth Biologic?
Birth Biologic provides expecting parents with a pathway to donate life-saving perinatal tissue, including the placenta and umbilical cord, immediately following childbirth. This donated tissue is rich in valuable stem cells, which hold immense potential for treating a range of life-threatening diseases and advancing critical medical research. The company prioritizes the safety and ethical integrity of its donation process, ensuring no adverse effects on the mother or newborn. Birth Biologic's core mission is to champion medical progress through responsible perinatal tissue donation, ultimately contributing to improved health outcomes and saving lives.
How much funding has Birth Biologic raised?
Birth Biologic has raised a total of $50K across 1 funding round:
Debt
$50K
Debt (2021): $50K with participation from PPP
Key Investors in Birth Biologic
PPP
Public-Private Partnership
What's next for Birth Biologic?
With the recent influx of substantial expansion capital, Birth Biologic is poised for significant operational scaling and strategic market expansion. The company's focus on perinatal stem cell donation places it at the forefront of regenerative medicine, a sector experiencing rapid innovation and increasing investment. Future endeavors will likely involve enhancing donation infrastructure, expanding research collaborations, and potentially broadening the scope of treatable conditions through stem cell therapies. This strategic financing is expected to fuel the company's mission to advance medical science and improve patient care.
See full Birth Biologic company page
